Ophthalmology | Special Reports

Faricimab up to Q16W noninferior to aflibercept Q8W in DME and nAMD

Dr. Karl Csaky, Dr. Charles Wykoff, Dr. Jeffrey Heier, 20210408000000

Intravitreal injections with anti-vascular endothelial growth factor (VEGF) agents are associated with significant treatment burden for patients with diabetic macular oedema (DME) and neovascular age-related macular degeneration (nAMD). At the Angiogenesis, Exudation, and Degeneration 2021 Virtual Congress, Dr Karl Csaky of Retina Foundation of the Southwest, Dallas, Texas, US, Dr Charles Wykoff of Retina Consultants of Texas, Houston, Texas, US, and Dr Jeffrey Heier of Ophthalmic Consultants of Boston, Boston, Massachusetts, US, presented results of four phase III trials that compared the efficacy and safety of the investigational bispecific antibody, faricimab, administered at up to Q16W dosing intervals, vs the decoy VEGF-A/placental growth factor (PIGF) receptor aflibercept at Q8W dosing intervals, in patients with retinal vascular diseases.

No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia

Roshini Claire Anthony, 20200628100001

Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.

Read highlights from AAO 2016 in the Eye on AAO e-Bulletins – now available to download

20161110051236

The 2016 Annual Meeting of the American Academy of Ophthalmology (AAO) was held in Chicago, USA, from 15−18 October 2016. A panel of renowned international clinicians in the field of ophthalmology contributed the articles for the Eye on AAO 2016 e-Bulletins, which feature conference highlights, reviews of hot topics discussed at the meeting, Asian and clinical relevance of few of the important topics.